- Home
- ACIU vs RCEL Comparison
ACIU vs RCEL Comparison
Compare ACIU & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- RCEL
- Stock Information
- Founded
- ACIU 2003
- RCEL 2020
- Country
- ACIU Switzerland
- RCEL United States
- Employees
- ACIU N/A
- RCEL N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- RCEL Medical/Dental Instruments
- Sector
- ACIU Health Care
- RCEL Health Care
- Exchange
- ACIU Nasdaq
- RCEL Nasdaq
- Market Cap
- ACIU 305.7M
- RCEL 310.6M
- IPO Year
- ACIU 2016
- RCEL N/A
- Fundamental
- Price
- ACIU $3.23
- RCEL $12.60
- Analyst Decision
- ACIU Strong Buy
- RCEL Hold
- Analyst Count
- ACIU 2
- RCEL 3
- Target Price
- ACIU $12.00
- RCEL $16.50
- AVG Volume (30 Days)
- ACIU 131.4K
- RCEL 109.3K
- Earning Date
- ACIU 11-05-2024
- RCEL 11-07-2024
- Dividend Yield
- ACIU N/A
- RCEL N/A
- EPS Growth
- ACIU N/A
- RCEL N/A
- EPS
- ACIU N/A
- RCEL N/A
- Revenue
- ACIU $48,505,404.00
- RCEL $60,040,000.00
- Revenue This Year
- ACIU N/A
- RCEL $34.73
- Revenue Next Year
- ACIU $938.44
- RCEL $54.61
- P/E Ratio
- ACIU N/A
- RCEL N/A
- Revenue Growth
- ACIU 4097200.00
- RCEL 32.24
- 52 Week Low
- ACIU $2.25
- RCEL $7.51
- 52 Week High
- ACIU $5.14
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- ACIU 54.88
- RCEL 66.15
- Support Level
- ACIU $3.11
- RCEL $11.63
- Resistance Level
- ACIU $3.41
- RCEL $13.82
- Average True Range (ATR)
- ACIU 0.23
- RCEL 0.82
- MACD
- ACIU 0.03
- RCEL 0.09
- Stochastic Oscillator
- ACIU 46.72
- RCEL 77.69
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.